124 related articles for article (PubMed ID: 22178548)
1. Observations of second primary malignancy in patients with multiple myeloma.
Ormerod A; Fausel CA; Abonour R; Kiel PJ
Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):113-7. PubMed ID: 22178548
[TBL] [Abstract][Full Text] [Related]
2. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
Palumbo A; Bringhen S; Kumar SK; Lupparelli G; Usmani S; Waage A; Larocca A; van der Holt B; Musto P; Offidani M; Petrucci MT; Evangelista A; Zweegman S; Nooka AK; Spencer A; Dimopoulos MA; Hajek R; Cavo M; Richardson P; Lonial S; Ciccone G; Boccadoro M; Anderson K; Barlogie B; Sonneveld P; McCarthy PL
Lancet Oncol; 2014 Mar; 15(3):333-42. PubMed ID: 24525202
[TBL] [Abstract][Full Text] [Related]
3. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Attal M; Lauwers-Cances V; Marit G; Caillot D; Moreau P; Facon T; Stoppa AM; Hulin C; Benboubker L; Garderet L; Decaux O; Leyvraz S; Vekemans MC; Voillat L; Michallet M; Pegourie B; Dumontet C; Roussel M; Leleu X; Mathiot C; Payen C; Avet-Loiseau H; Harousseau JL;
N Engl J Med; 2012 May; 366(19):1782-91. PubMed ID: 22571202
[TBL] [Abstract][Full Text] [Related]
5. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Palumbo A; Hajek R; Delforge M; Kropff M; Petrucci MT; Catalano J; Gisslinger H; Wiktor-Jędrzejczak W; Zodelava M; Weisel K; Cascavilla N; Iosava G; Cavo M; Kloczko J; Bladé J; Beksac M; Spicka I; Plesner T; Radke J; Langer C; Ben Yehuda D; Corso A; Herbein L; Yu Z; Mei J; Jacques C; Dimopoulos MA;
N Engl J Med; 2012 May; 366(19):1759-69. PubMed ID: 22571200
[TBL] [Abstract][Full Text] [Related]
6. How lenalidomide is changing the treatment of patients with multiple myeloma.
Dimopoulos MA; Terpos E; Niesvizky R
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S23-35. PubMed ID: 23816163
[TBL] [Abstract][Full Text] [Related]
7. Multiple myeloma and its therapies: to what extent do they contribute to the increased incidence of second malignant neoplasms?
Dasanu CA; Mewawalla P; Grabska J
Curr Med Res Opin; 2012 Jul; 28(7):1129-40. PubMed ID: 22533678
[TBL] [Abstract][Full Text] [Related]
8. Multiple myeloma and other malignancies: a pilot study from the Houston VA.
Munker R; Shi R; Lin D; Guo S; Hayes TG
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):102-6. PubMed ID: 24373789
[TBL] [Abstract][Full Text] [Related]
9. [Second primary malignancies after the treatment of multiple myeloma].
Makita S; Maruyama D
Nihon Rinsho; 2015 Jan; 73(1):162-6. PubMed ID: 25626323
[TBL] [Abstract][Full Text] [Related]
10. [Association of multiple myeloma and solid neoplasms: analysis of 13 cases].
Todolí Parra JA; Campo López C; Segura Huerta A; Alonso Estellés R; Saro Pérez E; Torrego Giménez A; Santaballa Bertrán A; Pastor Borgoñón M; Calabuig Alborch JR
Rev Clin Esp; 1999 Nov; 199(11):725-8. PubMed ID: 10638237
[TBL] [Abstract][Full Text] [Related]
11. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
[TBL] [Abstract][Full Text] [Related]
12. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
Ghobrial IM; Weller E; Vij R; Munshi NC; Banwait R; Bagshaw M; Schlossman R; Leduc R; Chuma S; Kunsman J; Laubach J; Jakubowiak AJ; Maiso P; Roccaro A; Armand P; Dollard A; Warren D; Harris B; Poon T; Sam A; Rodig S; Anderson KC; Richardson PG
Lancet Oncol; 2011 Mar; 12(3):263-72. PubMed ID: 21345726
[TBL] [Abstract][Full Text] [Related]
13. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
14. Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis.
Giri S; Barth P; Costa LJ; Olszewski AJ
J Geriatr Oncol; 2021 Mar; 12(2):256-261. PubMed ID: 32684352
[TBL] [Abstract][Full Text] [Related]
15. Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan.
Liu Y; Hou HA; Qiu H; Tang CH
Sci Rep; 2020 Sep; 10(1):14393. PubMed ID: 32873831
[TBL] [Abstract][Full Text] [Related]
16. Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.
Engelhardt M; Ihorst G; Landgren O; Pantic M; Reinhardt H; Waldschmidt J; May AM; Schumacher M; Kleber M; Wäsch R
Haematologica; 2015 Oct; 100(10):1340-9. PubMed ID: 26160877
[TBL] [Abstract][Full Text] [Related]
17. Novel lenalidomide-based combinations for treatment of multiple myeloma.
Cives M; Simone V; Brunetti O; Longo V; Silvestris F
Crit Rev Oncol Hematol; 2013 Jan; 85(1):9-20. PubMed ID: 22809697
[TBL] [Abstract][Full Text] [Related]
18. Role of thalidomide in the treatment of patients with multiple myeloma.
Morgan GJ; Davies FE
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S14-22. PubMed ID: 23827438
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
Fouquet G; Tardy S; Demarquette H; Bonnet S; Gay J; Debarri H; Herbaux C; Guidez S; Michel J; Perrot A; Serrier C; Miljkovic D; Avet Loiseau H; Facon T; Hulin C; Leleu X
Cancer; 2013 Oct; 119(20):3680-6. PubMed ID: 23921945
[TBL] [Abstract][Full Text] [Related]
20. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
